However, in HER2-overexpressing metastatic breast cancer patients, the emergence of de novo or intrinsic resistance to trastuzumab monotherapy is exceedingly high, ranging between 66 and 88% [5]. The gene discussed is ERBB2; the disease is breast cancer.